Skip to main
AGEN

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Agenus is leveraging its strong clinical data from the NEST and UNICORN trials to prioritize the initiation of the Phase 3 ROBBIN trial in the neoadjuvant setting for MSS-CRC patients, supported by a shift in resources to this program as well as a $340M private placement. With a potential early filing for approval based on the interim analysis, milestone payments from ongoing collaborations, and a ~5 year patent extension for bot/bal, Agenus is well-positioned to capitalize on the potential of its promising immunotherapy assets.

Bears say

Agenus is currently projected to have a difficult time achieving their $25 price target in the long-term, as their discounted cash flow analysis projects a negative terminal value and relies on relatively conservative assumptions for their leading product candidates. In addition, risks to the achievement of the price target include potential safety concerns, lower-than-expected efficacy in clinical trials, commercial competition, changes to programs and regulations, financing requirements, and potential issues with intellectual property protection.

Agenus (AGEN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Agenus (AGEN) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.